CompletedPhase 2

Comparison of SLx-4090 Combined With Statin Therapy Versus Statin Alone in Reducing LDL-C in Patients With Hyperlipidemia

United States133 participantsStarted 2009-01

Plain-language summary

The purpose of this study is to determine whether SLx-4090 in combination with statin therapy will reduce LDL-C in patients with hyperlipidemia more effectively than statin therapy alone.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * LDL-C \> or = 100 mg/dL * On stable statin therapy for at least 6 weeks Exclusion Criteria: * Coronary heart disease or risk factors for CHD

What they're measuring

Reduction in LDL-C

Timeframe: 12 weeks

Trial details

NCT IDNCT00810979

SponsorResponse Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2009-09

View on ClinicalTrials.gov More Hyperlipidemia trials